Experimental vaccine trains immune system to attack kidney tumors
NCT ID NCT00458536
First seen Feb 10, 2026 · Last updated Jun 23, 2026 · Updated 20 times
Summary
This study tested a personalized vaccine made from a patient's own tumor cells fused with immune cells (dendritic cells) to treat stage IV kidney cancer. The vaccine was given with a drug called GM-CSF to boost immune response. The main goal was to check safety and side effects in 38 participants, and to see if the vaccine triggered an immune response against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dendritic cell/tumor fusion vaccine with GM-CSF
What this could lead to
If successful, this approach could point toward a new way to stimulate the immune system to fight advanced kidney cancer.
What could go wrong
This is an early-phase trial with only 38 participants, so results may not apply broadly. The vaccine is personalized and complex, and side effects or lack of immune response are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.